Kiran Majumdar shaw’s

view about india

Presented by
Vidushi Bharti
Batch 2017-19
Roll no. 17026

In Partial Fulfilment of Post Graduation

Diploma in Management

Date of Presentation: 11th December, 2017

 INTRODUCTION
Kiran Mazumdar-Shaw is an Indian
billionaire entrepreneur. She is the chairman
and managing director of Biocon Limited, a
biotechnology company based in Bangalore, Net worth: 3.1 billion
USD (2017) Forbes
India and the chairperson of IIM-Bangalore.

Biocon introduced India’s indigenously developed recombinant human

insulin using a proprietary fermentation technology in 2004 and, along
with Wockhardt, was able to break the monopoly of innovators in
insulins by offering indigenously manufactured affordable alternatives, Awards: Padma Bhushan
thus enhancing access to this life-saving therapy.
 India’s future from Pharmaceutical industry’s
perspective
• India has successfully leveraged recombinant DNA technology
to deliver biopharmaceuticals, vaccines, genetically engineered
crops and enzymes.
• Currently, India is among the top 12 biotechnology
destinations in the world and ranks third in the Asia-Pacific
region.
• Today, ‘1 in 3’ children globally are immunised with a ‘Made in
India’ vaccine.
• It has created a notable bio-economy valued at $35 billion.
 India’s future from Pharmaceutical industry’s
perspective
• India pharmaceutical industries has an ambitious goal to become
$100 billion by 2025 and scale up to $200 billion by 2030.
• She believes that, by 2050, cancer will become manageable
through advances in the field of immuno-oncology, thus replacing
the need for chemotherapy and radiotherapy.
• Biotechnology in agriculture and farming has the potential to
address numerous challenges associated with food security in India
to improve yields and are resistant to pests, flooding and drought,
could make food cheaper, more nutritious and abundant.